News

Betrixaban, an FDA Fast Track-designated investigational drug, is an oral, once-daily Factor Xa inhibitor anticoagulant. John Curnutte, M.D. Ph.D., executive vice president, research and development at Portola, said:

The I-SPY 2 TRIAL, sponsored by QuantumLeap Healthcare Collaborative (QLHC), is a standing phase 2 randomized, controlled, multicenter study with an innovative adaptive design aimed to rapidly screen

Pablo Lapuerta, M.D., Lexicon’s executive vice president and chief medical officer, said: "The inTandem4 Phase 2 dose-ranging study represents the first of three clinical trials of sotagliflozin that

Debiopharm completed a double-blind randomized phase II study evaluating the efficacy of two different doses of intravenous and oral Debio 1450 compared to intravenous vancomycin and oral linezolid

The phase III SOLO-2 trial randomized 295 patients with documented germline BRCA1 or BRCA2 mutations who had received at least two prior lines of platinum-based chemotherapy. It showed

The company signed an agreement with the US Food and Drug Administration (FDA) regarding the trial’s design. The phase 3 HOPE (Hemoglobin Oxygen Affinity Modulation to Inhibit HbS

SCD is the most common inherited blood disorder in the United States and is caused by a genetic mutation that results in the production of abnormal hemoglobin, the

Vanda has entered into a License Agreement (the License Agreement) with Taro Pharmaceuticals U.S.A., Inc. and Taro Pharmaceutical Industries Ltd. (collectively, Taro) to resolve Vanda's patent litigation against

The company submitted a biologics licence application (BLA) to the US Food and Drug Administration (FDA) to market the vaccine for the prevention of herpes zoster (shingles) in